• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Development of a Novel Strategy for Targeted Delivery of siRNA to B lymphocytes 
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Development of a Novel Strategy for Targeted Delivery of siRNA to B lymphocytes
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Development of a Novel Strategy for Targeted Delivery of siRNA to B lymphocytes
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Development of a Novel Strategy for Targeted Delivery of siRNA to B lymphocytes

    View/Open
    Muhammad, Hawzheen Aziz 250314.pdf (29.26Mb)
    Publisher
    Queen Mary University of London
    Metadata
    Show full item record
    Abstract
    This study describes “proof of concept” experiments for development of a novel therapy to target B cells in pathological settings such as cancer and inflammation. Targeted biological therapies including monoclonal antibodies (mAbs) have revolutionised medicine, thus biological therapies are increasingly used in the treatment of patients with a range of diseases including cancer. However, despite significant progress in the treatment modalities, haematological malignancies remain a leading cause of cancer related mortality. Though RNA interference (RNAi) is a promising strategy for cancer gene therapy, targeted delivery of siRNAs into cells is a key challenge to their therapeutic application. One approach to target intracellular delivery could be to harness cell surface receptors that are internalised upon ligation by mAb. Thus, single-chain fragment of variable regions (scFv) mediated siRNA delivery into diseased B cells via cell surface receptors is a promising strategy. The approach involves generating an engineered scFv-protamine fusion protein to deliver siRNA specifically to B cells via CD22. For this purpose, gene constructs that combine the VH and VL of mAb (Cy34.1.2) targeting mouse CD22 and HA22, a scFv that targets human CD22, were fused to a truncated protamine peptide. Gene constructs have been produced for the expression of fusion proteins using a range of expression systems. HA22 fusion protein was expressed as secretable protein in serum-free cultures of mammalian cells. The protein was shown to retain specificity of binding to CD22 on B cells with subsequent internalisation and was also able to deliver fluorescently-labelled siRNA into B cells. The feasibility of harnessing protamine peptide for siRNA delivery was verified in tumour cells expressing αvβ6 integrin using the A20FMDV2-protamine peptide. Furthermore, siRNAs to MCL1 and PLK1 genes delivered with HA22 fusion protein to malignant B cells induced apoptosis. This study demonstrates the potential for systemic, cell-type specific, antibody-mediated siRNA delivery.
    Authors
    Muhammed, Hawzheen Aziz
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/8774
    Collections
    • Theses [3706]
    Copyright statements
    The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.